Core Viewpoint - Heng Rui Medicine (01276) announced that its subsidiary, Guangdong Heng Rui Medicine Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-1139 injection, which is expected to begin soon [1] Group 1: Product Development - SHR-1139 injection is a self-developed biological product aimed at treating ulcerative colitis, expected to enhance treatment by inhibiting inflammatory responses and maintaining epithelial barriers [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-1139 injection project has reached approximately 71.28 million yuan [1]